CI Global Health Sciences Corporate Class



As of July 21, 2023 CI Global Health Sciences Corporate Class Y (NL 4926) merged into (NL 324)

FUND OVERVIEW

This fund invests primarily in equity and equity-related securities of companies around the world that specialize in the health care or medical industry.

FUND DETAILS


Inception date	August 2000
Total net assets (\$CAD) As at 2023-07-31	\$146.8 million
NAVPS As at 2023-08-28	\$26.7061
MER (%) As at 2023-03-31	1.24
Management fee (%)	0.90
Asset class	Sector Equity
Currency	USD
Minimum investment	\$500 initial/\$25 additional
Distribution frequency	Quarterly
Last distribution	\$0.5033

PERFORMANCE²



As at 2023-07-31

Growth of \$10,000 (since inception date) 80k \$54,013 60k 40k 20k 0k 14 04 06 08 12 02 10 16 18 20 22





Risk rating¹

	Low to nedium	Medium	Medium to high	High	
--	------------------	--------	-------------------	------	--

FUND CODES

F	324
A	ISC 301 DSC SO [*] 401 LL SO 1401
Р	90324

*No new purchases directly into switch only funds.

Average annual compound returns

YTD	1 Mo	3 Mo	6 Mo	1 Y	3 Y	5 Y	10 Y	Inception*
2.98%	0.33%	0.16%	3.62%	3.01%	5.23%	2.31%	4.40%	7.61%

*Since inception date

DISTRIBUTION HISTORY³

Payable date	Total	Payable date	Total
2022-03-25	0.5033	2020-03-20	0.4395
2021-03-26	0.1714	2019-12-13	0.2744
2020-12-18	0.2724	2019-09-27	0.3063
2020-09-25	0.2584	2019-06-21	0.2883
2020-06-26	0.1886	2019-03-22	0.4530

MANAGEMENT TEAM





Peter Hofstra

CI Global Health Sciences Corporate Class



As of July 21, 2023 CI Global Health Sciences Corporate Class Y (NL 4926) merged into (NL 324)

PORTFOLIO ALLOCATIONS⁴

(%)
74.97
21.57
3.46

Sector allocation	(%)
Healthcare	91.32
Exchange Traded Fund	3.65
Cash and Cash Equivalent	3.46
Consumer Services	1.44
Other	0.13

(%)
78.20
7.62
7.27
4.12
2.61
0.13
0.05

TOP HOLDINGS

TOP HOLDINGS	Sector	(%)
1. UnitedHealth Group Inc	Healthcare Services	8.39%
2. Eli Lilly and Co	Drugs	6.68%
3. Johnson & Johnson	Drugs	6.25%
4. Humana Inc	Healthcare Services	5.68%
5. AstraZeneca PLC	Drugs	5.25%
6. Merck & Co Inc	Drugs	5.08%
7. Zoetis Inc Cl A	Drugs	4.25%
8. Novo Nordisk A/S CI B	Drugs	4.12%
9. SPDR S&P Biotech ETF (XBI)	Exchange Traded Fund	3.65%
10. Roche Holding AG - Partcptn	Drugs	3.55%
11. Usd Cash Sweep	Cash and Cash Equivalent	3.39%
12. Amgen Inc	Drugs	3.25%
13. Thermo Fisher Scientific Inc	Healthcare Equipment	2.90%
14. Stryker Corp	Healthcare Equipment	2.90%
15. Edwards Lifesciences Corp	Healthcare Equipment	2.71%



As at 2023-07-31

Over 35,000 financial advisors have chosen CI Global Asset Management as a partner. We believe that Canadians have the best opportunity for investments success by using the services of a professional financial advisor. Learn more at ci.com.

¹ The risk level of a fund has been determined in accordance with a standardized risk classification methodology in National Instrument 81-102, that is based on the fund's historical volatility as measured by the 10-year standard deviation of the fund's returns. Where a fund has offered securities to the public for less than 10 years, the standardized methodology requires that the standard deviation of a reference mutual fund or index that reasonably approximates the fund's standard deviation be used to determine the fund's risk rating. Please note that historical performance may not be indicative of future returns and a fund's historical volatility may not be indicative of future volatility.

² Commissions, trailing commissions, management fees and expenses all may be associated with mutual fund investments. Please read the prospectus before investing. The indicated rates of return are the historical annual compounded total returns net of fees and expenses payable by the fund (except for figures of one year or less, which are simple total returns) including changes in security value and reinvestment of all dividends/distributions and do not take into account sales, redemption, distribution or optional charges or income taxes payable by any securityholder that would have reduced returns. Mutual funds are not guaranteed, their values change frequently, and past performance may not be repeated.

³ Please refer to the fund's simplified prospectus for distribution information.

⁴ Portfolio allocations will fluctuate over the life of the mutual fund as the portfolio holdings and market value of each security changes. The portfolio manager(s) may change the portfolio allocations in some or all of the sectors.

The contents are not to be used or construed as investment advice or as an endorsement or recommendation of any entity of security discussed.

Certain statements contained in this communication are based in whole or in part on information provided by third parties and CI has taken reasonable steps to ensure their accuracy.

The rates of return are used only to illustrate the effects of the compound growth rate and are not intended to reflect future values or returns on investment in an investment fund.

The "Growth of \$10,000 invested" chart shows the final value of a hypothetical \$10,000 investment in securities in this class/series of the fund as at the end of the investment period indicated and is not intended to reflect future values or returns on investment in such securities.

Management Expense Ratio ("MER") represents the trailing 12-month management expense ratio, which reflects the cost of running the fund, inclusive of applicable taxes including HST, GST and QST (excluding commissions and other portfolio transaction costs) as a percentage of daily average net asset value the period, including the fund's proportionate share of any underlying fund(s) expenses, if applicable. The MER is reported in each fund's Management Report of Fund Performance ("MRFP"). MRFPs can be found within the Documents tab on ci.com.

CI Global Asset Management is a registered business name of CI Investments Inc.

©CI Investments Inc. 2023. All rights reserved.

Published August 2023